Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600120206) titled 'A clinical trial to evaluate the efficacy and safety of HB0043(IL-17A/IL-36R bispecific antibody) in adult subjects with moderate to severe acne' on March 10.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Shandong Provincial Institute of Dermatology and Venereology
Condition:
Acne
Intervention:
Intervention Group:The subjects received hb0043300mg for injection from W0, and were administered subcutaneously once every two weeks (q2w). The last administration was at W14, and the last visit was at w16
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-03...